PRESS RELEASES More events are coming soon. Keyword Search Year: 2022202120202019201820172016201520142013 11/21/22 Summary Toggle TRACON Pharmaceuticals Announces Dosing of First Patient in Phase 1/2 Trial of YH001 in Combination with Envafolimab and Doxorubicin in Front Line Sarcoma Printer Friendly PDF Version 11/14/22 Summary Toggle TRACON Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update Printer Friendly PDF Version 10/31/22 Summary Toggle TRACON to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 14, 2022 Printer Friendly PDF Version 10/06/22 Summary Toggle TRACON Pharmaceuticals Announces Results of Independent Data Monitoring Committee Review of 12 Week Safety Data from ENVASARC Phase 2 Pivotal Trial - Trial to Proceed as Planned Printer Friendly PDF Version 09/14/22 Summary Toggle TRACON Pharmaceuticals Announces Fast Track Designation by the FDA for Envafolimab for the Treatment of the Soft Tissue Sarcoma Subtypes of UPS and MFS Printer Friendly PDF Version 09/07/22 Summary Toggle TRACON Pharmaceuticals Announces Participation at Upcoming Investor Conferences Printer Friendly PDF Version 09/06/22 Summary Toggle TRACON Pharmaceuticals Announces $35 Million Non-Dilutive Debt Financing with Runway Growth Capital Printer Friendly PDF Version 08/29/22 Summary Toggle TRACON Pharmaceuticals Announces Approval of IND for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with Envafolimab Printer Friendly PDF Version 08/10/22 Summary Toggle TRACON Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update Printer Friendly PDF Version 08/10/22 Summary Toggle TRACON Pharmaceuticals Announces Results of Independent Data Monitoring Committee Review of Safety Data from ENVASARC Pivotal Trial Printer Friendly PDF Version Pagination Current page 1 Page 2 Page 3 Page 4 … Next page Next Last page Last
